Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
ASX:MYX
Price:
7.12 AUD
-0.28%
Market Closed
Updated:
May 9, 2024
Mayne Pharma Group Ltd
Interest Income Expense
|
Mayne Pharma Group Ltd
Interest Income Expense Peer Comparison
Comparables:
RCE
NEU
BOT
PBP
C
CU6
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Interest Income Expense
-AU$19.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Interest Income Expense
-AU$451.5k
|
CAGR 3-Years
-254%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Interest Income Expense
AU$208k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Interest Income Expense
AU$17.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Probiotec Ltd
ASX:PBP
|
Interest Income Expense
-AU$6m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-15%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Interest Income Expense
AU$1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Interest Income Expense?
Interest Income Expense
-19.2m
AUD
-19.2m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Interest Income Expense amounts to -19.2m AUD.
What is Mayne Pharma Group Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-12%
-12%
Over the last year, the Interest Income Expense growth was -125%. The average annual Interest Income Expense growth rates for Mayne Pharma Group Ltd have been 13% over the past three years , -12% over the past five years .
You don't have any saved screeners yet
